


Please type a plus sign (+) inside this box 

PTO/SB/05 (03-01)
Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL		Attorney Docket No. VPI/02-113 US		22389 U.S. PTO 10/677631
		First Inventor David Lauffer		
		Title Piperazine and Piperidine Derivatives		
(Only for new nonprovisional applications under 37 CFR 1.53(b))		Express Mail Label No. EV 317 172 952 US		
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		ADDRESS TO: MS Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		
1. ☐ Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing) 2. ☐ Applicant claims small entity status. See 37 CFR 1.27. 3. ☒ Specification [Total Pages 51] (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 4. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets 5. Oath or Declaration [Total Pages 3] a. ☒ Newly executed (original or copy) (UNEXECUTED) b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. ☐ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. ☐ Application Data Sheet. See 37 CFR 1.76		7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. ☐ Computer Readable Form (CRF) b. Specification Sequence Listing on: i. ☐ CD-ROM or CD-R (2 copies); or ii. ☐ paper c. ☐ Statements verifying identity of above copies		
		ACCOMPANYING APPLICATIONS PARTS		
		9. ☐ Assignment Papers (cover sheet & document(s)) 10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney 11. ☐ English Translation Document (if applicable) 12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations 13. ☐ Preliminary Amendment 14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. ☒ Other: Express Mail Page		
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____ Prior application information: Examiner _____ Group / Art Unit: _____ For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.				
19. CORRESPONDENCE ADDRESS				
☒ Customer Number or Bar Code Label		27916		or ☐ Correspondence address below
Name	Nandakumar Govindaswamy Vertex Pharmaceuticals Incorporated			
Address	130 Waverly Street			
City	Cambridge	State	Massachusetts	Zip Code 02139-4242
Country	USA	Telephone	(617) 444-6619	Fax (617) 444-6483
Name (Print/Type)	Nandakumar Govindaswamy	Registration No. (Attorney/Agent)	Ltd. Recognition	
Signature			Date	October 2, 2003

Attorney Docket No.: VPI/02-113 US

Certificate Of Mailing Under 37 C.F.R. § 1.10

Express Mailing No. EV 317 172 952 US **Date of Deposit:** October 2, 2003

I hereby certify that the following documents:

1. Utility Transmittal for Patent Application;
2. Specification 51 pages (Desc. 38 pgs, Claims 12 pgs., Abstract 1 pg); and
3. Return postcard receipt.

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the MS Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Karen DiRocco

(type or printed name of person mailing document(s))



(signature of person mailing document(s))


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Nandakumar Govindaswamy is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Vertex Pharmaceuticals, Inc. to prepare and prosecute patent applications wherein the patent application is assigned to Vertex Pharmaceuticals, Inc., and the attorney or agent of record in the applications is a registered practitioner who is an employee of Vertex Pharmaceuticals, Inc. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Nandakumar Govindaswamy ceases to lawfully reside in the United States, (ii) Nandakumar Govindaswamy's employment with Vertex Pharmaceuticals, Inc. ceases or is terminated, or (iii) Nandakumar Govindaswamy's current Employment Authorization card expires.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 24, 2004

A handwritten signature in dark ink, appearing to read "Harry Moatz", is written over a horizontal line.

Harry Moatz,
Director of Enrollment and Discipline